Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 3/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | BACE1 | P56817 | 3/20 | 0.54 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23931322 | 1.00 | CASP1 (0.61) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL18087495 | 0.91 | CASP1 (0.63) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL19970821 | 0.91 | CASP1 (0.63) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL24310825 | 0.91 | CASP1 (0.63) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL478003 | 0.90 | OPRD1 (0.62) | CASP1OPRD1BACE1BACE2 | |
| SCHEMBL27825824 | 0.88 | CASP1 (0.67) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL9241543 | 0.88 | CASP1 (0.67) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL29030118 | 0.88 | CASP1 (0.64) | CASP1OPRD1BACE1BACE2CASP3 | |
| SCHEMBL2037941 | 0.87 | CASP1 (0.67) | CASP1CASP3CASP7CASP9REN | |
| SCHEMBL6376450 | 0.86 | CASP1 (0.57) | CASP1OPRD1BACE1BACE2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090232866-A1 | Oligopeptides as coating material for medical products | HEMOTEQ AG (DE) | 2009-09-17 | — | — | US | claimed |
| JP-2007507264-A | — | — | 2007-03-29 | — | — | JP | claimed |
| EP-1670502-A2 | OLIGOPEPTIDES AS COATING MATERIAL FOR MEDICAL PRODUCTS | Hemoteq GmbH (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005039629-A2 | CASPASE INHIBITORS AS COATING MATERIEL FOR MEDICAL PRODUCTS FOR INHIBITING RESTENOSIS | HEMOTEQ GMBH (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20030105046-A1 | Interleukin converting enzyme (ICE) and central nervous system damage | THE GENERAL HOSPITAL CORPORATION | 2003-06-05 | — | — | US | claimed |
| WO-1998057664-A9 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | YUAN JUNYING (US) | 1999-04-08 | — | — | WO | claimed |
| WO-1998057664-A1 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-12-23 | — | — | WO | claimed |
| US-20240115649-A1 | CASPASE INHIBITION TO ENHANCE REGENERATION AND REPAIR AFTER SKIN OR GUT INJURY AND TO TREAT BACTERIAL OR VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| US-20230313303-A1 | COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA | MEDICAL COLLEGE WISCONSIN INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230218705-A1 | CASPASE INHIBITORS TO ENHANCE INJURY REPAIR AND TO TREAT BACTERIAL AND VIRAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-20230218726-A1 | TREATMENT OF VIRAL CONJUNCTIVITIS | OKOGEN, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230138927-A1 | METHODS FOR ASSESSING THE SEVERITY OF, AND FOR INHIBITING, PRO-INFLAMMATORY RESPONSES WITH TOTAL CELL-FREE DNA | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| EP-4153265-A1 | COMPOSITIONS AND METHODS FOR REDUCING CELL-FREE DNA | The Medical College of Wisconsin, Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-1361897-A2 | METHODS FOR INHIBITING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2003-11-19 | — | — | EP | disclosed |
| US-20030105046-A1 | Interleukin converting enzyme (ICE) and central nervous system damage | THE GENERAL HOSPITAL CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-20020136714-A1 | Treatment of inflammatory diseases and/or diseases characterized by cell deaths, as well as cancers, autoimmune disorders, infections | HORVITZ H ROBERT (US) | 2002-09-26 | — | — | US | disclosed |
| WO-2002038035-A2 | METHODS FOR INHIBITING PAIN | THE GENERAL HOSPITAL CORPORATION (US) | 2002-05-16 | — | — | WO | disclosed |
| US-5962301-A | Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1998057664-A9 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | YUAN JUNYING (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998057664-A1 | INTERLEUKIN CONVERTING ENZYME (ICE) AND CENTRAL NERVOUS SYSTEM DAMAGE | THE GENERAL HOSPITAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |